Aradigm Receives CRL for Linhaliq, Citing Quality and Data Concerns

Drug Industry Daily
The FDA issued a complete response letter to Aradigm over its Linhaliq (ciprofloxacin liposomal) submission for non-cystic fibrosis bronchiectasis, a severe, rare lung disease frequently associated with chronic lung infections, saying the drug could not be approved in its current form.

To View This Article:


Subscribe To Drug Industry Daily